Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just grab another 5K

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Mar 04, 2021 10:46am

118 Views

Post# 32714594

RE:Just grab another 5K

Might be a bargain but as long as we are on CA exchange this stock is going to langush IMO. Need USA institions to wade in / list on NASDAQ. Dan and mgmt can state they are under valued all they want but we aren't in the right market to get noticed / or bought... tired of bs CA exchange, more games than even the US...

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland